Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IMUC $1.00 0.0794 +8.62%
CYTK $4.14 0.2800 +7.25%
AVEO $1.27 0.0800 +6.72%
DNDN $1.50 0.0800 +5.63%
PPHM $1.46 0.0700 +5.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NYMX $4.15 -0.6000 -12.63%
XNCR $9.69 -0.7700 -7.36%
RNN $0.71 -0.0531 -6.99%
OGXI $2.80 -0.2000 -6.67%
ONCY $0.73 -0.0500 -6.41%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | Next > | Last >>

Better Drug Ads, Fewer Side Effects

(New York Times) Feb 9, 2011 - ON Aug. 8, 1997, Michael Friedman, then a deputy commissioner of the United States Food and Drug Administration, announced a policy change that let loose the forces of direct-to-consumer pharmaceutical television advertising.
read article (free registration required) 

Lilly CEO Says Industry, Public Policy Must Pave Way For Innovation

(Yahoo! Finance) Feb 10, 2011 - A new approach to research, along with public policies that support medical innovation, will help biopharmaceutical companies address stubborn diseases with potentially devastating personal and financial consequences, such as cancer and Alzheimer's disease, according to John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company.
read article 

FDA Panel Urges Stricter Standards for Cancer Drugs

( Feb 8, 2011 - An FDA advisory panel said Tuesday that the agency should require companies seeking accelerated approval for cancer drugs to submit at least one controlled trial to bolster their case.
read article 

Gene Test Could Solve Prostate Cancer Riddle and Spare Thousands From Surgery

(Cancer Research UK) Feb 9, 2011 - A genetic pattern could predict how aggressive prostate cancer is before treatment, and whether the disease will come back in men who have already been treated, according to research published in the Lancet Oncology.
read press release 

Birth Defect Risk Slightly Higher for Kids of Male Cancer Survivors

(Bloomberg Businessweek) Feb 8, 2011 - Men who have had cancer are at a slightly higher risk of bearing children with congenital problems such as a cleft palate compared to their peers with no history of cancer, according to new research.
read article 

Breast-Cancer Study Questions Lymph Node Removal

(Washington Post) Feb 9, 2011 - Many women with early breast cancer do not appear to need removal of their lymph nodes, as is often recommended, according to a federally funded study released Tuesday.
read article (free registration required) 

Saving Lives From Anal Cancer

(NYT Well Blog) Feb 9, 2011 - Paulette Crowther’s three children were grown and she was plotting a midlife career change when a routine colonoscopy picked up cancer, but not of the colon — of the anus.
read article (free registration required) 

Gene Test May Cut Need for Prostate Cancer Surgery

(Reuters) Feb 8, 2011 - A genetic pattern could predict how aggressive prostate cancer is, potentially saving many men with less threatening tumors from undergoing unnecessary and life changing surgery, scientists said on Wednesday.
read article 

Cancer to Kill 1.3 Million in Europe in 2011

(Reuters) Feb 8, 2011 - Fewer than 1.3 million people will die from cancer in Europe this year as death rates from the disease fall, researchers said Wednesday, except that more women are dying of lung cancer in every country except Britain.
read article 

MicroRNA Hinders Enzyme That Promotes Breast Cancer Spread to Brain

(Baylor) Feb 8, 2011 - A small piece of genetic material stops the activity of an enzyme known to promote the spread of breast tumors to the brain, said a group of researchers at Baylor College of Medicine.
read press release 

Amgen Pushes Ahead With 'Son of Dmab' For Treating Broken, Frail Bones

(Xconomy) Feb 9, 2011 - Folks who follow Amgen closely know there’s really been one main theme to this story the past couple years—Dmab, Dmab, Dmab.
read article 

AP Pharma to Meet FDA on Nausea Drug Resubmission

(Reuters) Feb 9, 2011 - A.P. Pharma Inc said it arranged a meeting with U.S. health regulators to clarify issues before resubmitting an approval application for its lead product, and is seeking financing to fund its operations beyond the second quarter.
read article 

New European Guidelines on Bowel Cancer Screening and Diagnosis

(Cancer Research UK) Feb 8, 2011 - The first-ever set of EU guidelines for bowel cancer screening and diagnosis has been published.
read press release 

An Accelerated Pathway for Targeted Cancer Therapies

(ESMO) Feb 7, 2011 - Why do we need a well-defined pathway for the accelerated development and approval of targeted cancer therapies and companion diagnostics?
read press release 

Aetna Recognized by National Comprehensive Cancer Network for Evidence-Based Approach to Cancer Care

(Yahoo! Finance) Feb 8, 2011 - The National Comprehensive Cancer Network® (NCCN) has praised Aetna for its evidence-based approach to drugs used to treat cancer.
read article 

Geron CEO Steps Down, Interim Named

(Silicon Valley/San Jose Business Journal) Feb 9, 2011 - Geron Corp. on Wednesday named Chief Financial Officer David L. Greenwood president, member of the board and interim chief executive.
read article 

Health Law Provision Raises Antitrust Concerns

(New York Times) Feb 8, 2011 - The new health care law encourages collaboration by doctors and hospitals for cost savings, but a split has developed here as to just how far they can go without running afoul of antitrust laws.
read article (free registration required) 

Large Biotechs: Getting Old, Breaking Down

(TheStreet) Feb 9, 2011 - Sanofi-Aventis' protracted effort to acquire Genzyme appears to be at the denouement but biotech investors shouldn't be throwing a victory party. Far from being a celebratory event, the Genzyme takeover is another reminder that large-cap biotechs are aging -- and not well.
read article 

Lilly Collaboration with Outside Researchers Yields First Deal

(Indianapolis Business Journal) Feb 8, 2011 - Indianapolis-based Eli Lilly and Co. has struck its first deal under an open-collaboration program launched last year to evaluate the potential of compounds synthesized in university and biotech labs.
read article 

Novartis Unit Has Ten Biosimilars in Pipeline - Paper

(Reuters) Feb 9, 2011 - Novartis's generics unit Sandoz is working on eight to 10 new biosimilar molecules to cement its position as leading maker of copycat versions of pricey biotech drugs, the unit's head told Handelsblatt.
read article 

Breast Cancer Patients' Quality of Life Returns Slowly in the Year After Surgery

(LAT Booster Shots Blog) Feb 7, 2011 - Breast cancer survival rates have improved in recent years, and women have more treatment choices, including -- in cases of early-stage cancer -- the opportunity to forgo chemotherapy. A new study shows, however, that women who undergo chemotherapy experience more symptoms in the year after surgery.
read article (free registration required) 

Bevacizumab in the Treatment of Advanced Ovarian Cancer

(ASCO Connection Blog) Feb 8, 2011 – Introduction: January 2011 issue: Two randomized trials of primary chemotherapy with bevacizumab ([Gynecologic Oncology Group] GOG 0218 and ICON7) were presented and discussed at the 2010 Annual Meetings of ASCO, the European Society for Medical Oncology (ESMO), and the International Gynecologic Cancer Society (ICGS).
read article 

FDA Says Six Drug Firms Didn't Finish Follow-Ups

(Wall Street Journal) Feb 8, 2011 - Federal officials Tuesday questioned six companies that make cancer drugs about their failure to complete follow-up studies they promised to conduct in exchange for accelerated approval.
read article (paid subscription required) 

Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer

(Genentech) Feb 7, 2011 - Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.
read press release 

Avastin Helps Ovarian Cancer Patients Live Longer

(Reuters) Feb 8, 2011 - Roche's top-selling drug Avastin helps women with ovarian cancer live significantly longer without their disease getting worse, a late-stage trial showed, giving the troubled drug a much needed boost.
read article